前列腺癌基金会激素敏感性前列腺癌生物标志物工作组会议总结
本文总结了前列腺癌基金会于2020年8月召开的工作组会议,聚焦转移性激素敏感性前列腺癌(mHSPC)的生物标志物。会议讨论了全身治疗的临床与生物学证据现状,重点规划生物标志物的生成、验证及临床实施路径,以指导个体化治疗选择。
要点
- 雄激素剥夺治疗仍是mHSPC的骨架治疗。
- 多西他赛、阿比特龙+泼尼松、恩扎卢胺和阿帕他胺均显示 upfront 联合ADT的生存获益。
- 目前缺乏基于生物学驱动因素的高水平临床证据来指导治疗选择。
核心结论
- mHSPC治疗选择缺乏基于生物标志物的高级别证据,需推进生物标志物研究以指导个体化治疗。
研究设计与样本
- 前列腺癌基金会于2020年8月召开工作组会议,总结mHSPC全身治疗的临床与生物学证据,并规划生物标志物研究路径。
主要发现
- 多西他赛、阿比特龙+泼尼松、恩扎卢胺和阿帕他胺联合ADT upfront治疗均显示生存获益。
- 目前尚无基于疾病生物学驱动因素的高水平临床证据用于治疗选择。
临床怎么用
- 临床决策仍需依据现有证据,同时关注生物标志物研究进展以未来指导治疗选择。
局限性
- 会议总结未提供具体生物标志物验证数据或治疗选择算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Androgen deprivation therapy remains the backbone therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, several treatments, including docetaxel, abiraterone + prednisone, enzalutamide, and apalutamide, have each been shown to demonstrate survival benefit when used upfront along with androgen deprivation therapy. However, treatment selection for an individual patient remains a challenge. There is no high level clinical evidence for treatment selection among these choices based on biological drivers of clinical disease. In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which are summarized here. This meeting covered the state of clinical and biological evidence for systemic therapies in the mHSPC space, with emphasis on charting a course for the generation, interrogation, and clinical implementation of biomarkers for treatment selection.
引用
- Hofmann MR, Hussain M, Dehm SM, et al. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2020. PMID: 33373705. doi:10.1016/j.urology.2020.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。